Rate Video

EHA 2020 | UKALL2011: ABL-class fusions & TKIs

Anthony Moorman • 22 Jun 2020

Acute Lymphoblastic Leukemia Leukemia Imatinib

ALLTogether1 UKALL2011

Anthony Moorman, PhD, Newcastle University, Newcastle, UK discusses preliminary data from UKALL2011, focussing on ABL-class fusion acute lymphoblastic leukemia (ALL) and the use of tyrosine kinase inhibitors (TKIs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Novel prognostic index for pediatric ALL

Anthony Moorman • 22 Jun 2020

Combining MRD with genetic knowledge in ALL

Anthony Moorman • 14 Jun 2018

Redefining low risk high hyperdiploidy in pediatric ALL

Anthony Moorman • 8 Jun 2021

Prognostic factors in adult ALL patients

Anthony Moorman • 10 Nov 2020

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig